By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. (ACXP)

NASDAQ Currency in USD
$110.00
-$1.17
-1.05%
Last Update: 18 Jul 2026, 15:53
$164.89m
Market Cap
-24.94
P/E Ratio (TTM)
Forward Dividend Yield
$77.29-$133.67
52 Week Range

ACXP Stock Price Chart

Explore Acurx Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ACXP price movements and trends.

ACXP Company Profile

Discover essential business fundamentals and corporate details for Acurx Pharmaceuticals, Inc. (ACXP) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

25 Jun 2021

Employees

4.00

CEO

David Luci

Description

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.

ACXP Financial Timeline

Browse a chronological timeline of Acurx Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 14 Aug 2026

EPS estimate is -$0.42.

Earnings released on 12 May 2026

EPS came in at -$0.62 falling short of the estimated -$0.59 by -5.08%.

Earnings released on 13 Mar 2026

EPS came in at -$0.31 surpassing the estimated -$1.01 by +69.31%.

Earnings released on 12 Nov 2025

EPS came in at -$1.23 surpassing the estimated -$1.61 by +23.60%.

Earnings released on 11 Aug 2025

EPS came in at -$1.89 surpassing the estimated -$2.00 by +5.50%.

Stock split effective on 5 Aug 2025

Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 12 May 2025

EPS came in at -$2.20 falling short of the estimated -$0.15 by -1.37k%.

Earnings released on 17 Mar 2025

EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%.

Earnings released on 12 Nov 2024

EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%.

Earnings released on 9 Aug 2024

EPS came in at -$0.26 surpassing the estimated -$0.28 by +7.14%.

Earnings released on 14 May 2024

EPS came in at -$0.28 falling short of the estimated -$0.24 by -16.67%.

Earnings released on 15 Mar 2024

EPS came in at -$0.38 falling short of the estimated -$0.26 by -46.15%.

Earnings released on 13 Nov 2023

EPS came in at -$0.24 surpassing the estimated -$0.28 by +14.29%.

Earnings released on 14 Aug 2023

EPS came in at -$0.28 surpassing the estimated -$0.29 by +3.45%.

Earnings released on 12 May 2023

EPS came in at -$0.25 surpassing the estimated -$0.34 by +26.47%.

Earnings released on 16 Mar 2023

EPS came in at -$0.28 falling short of the estimated -$0.25 by -12.00%.

Earnings released on 14 Nov 2022

EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%.

Earnings released on 15 Aug 2022

EPS came in at -$0.26 surpassing the estimated -$0.35 by +25.71%.

Earnings released on 11 May 2022

EPS came in at -$0.26 surpassing the estimated -$0.33 by +21.21%.

Earnings released on 17 Mar 2022

EPS came in at -$0.23 surpassing the estimated -$0.40 by +42.50%.

Earnings released on 12 Nov 2021

EPS came in at -$0.46 .

Earnings released on 16 Aug 2021

EPS came in at -$0.57 .

ACXP Stock Performance

Access detailed ACXP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run